What is HC Wainwright’s Forecast for MBRX Q4 Earnings?

Moleculin Biotech, Inc. (NASDAQ:MBRX) – Research analysts at HC Wainwright issued their Q4 2024 earnings estimates for shares of Moleculin Biotech in a note issued to investors on Monday, March 3rd. HC Wainwright analyst V. Bernardino anticipates that the company will earn ($1.33) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Moleculin Biotech’s current full-year earnings is ($7.98) per share. HC Wainwright also issued estimates for Moleculin Biotech’s FY2025 earnings at ($3.31) EPS.

Several other equities research analysts have also issued reports on the company. Maxim Group lowered Moleculin Biotech from a “buy” rating to a “hold” rating in a report on Wednesday, February 12th. StockNews.com started coverage on Moleculin Biotech in a report on Wednesday. They issued a “sell” rating on the stock.

Moleculin Biotech Stock Performance

Shares of NASDAQ:MBRX opened at $1.16 on Wednesday. Moleculin Biotech has a 52 week low of $0.40 and a 52 week high of $10.35. The firm has a 50 day simple moving average of $1.50 and a 200 day simple moving average of $2.13.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.